Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Atripla

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Atripla was produced by Gilead Sciences.

MSD claims EU approval for two HIV products

MSD claims EU approval for two HIV products

Merck has suggested Delstrigo is slightly more effective than Gilead’s widely-prescribed Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate), which made $1.3bn in sales last year.

Gilead gets EU nod for TAF-based triple therapy for HIV

Gilead gets EU nod for TAF-based triple therapy for HIV Atripla in 20016. ... Since then, Atripla has grown into a $3bn-plus product. "People living with HIV today are increasingly likely to be receiving treatment for other conditions - such as heart and liver disease -

ViiV and Janssen take long-acting HIV regimen into phase III

ViiV and Janssen take long-acting HIV regimen into phase III Gilead currently dominates the HIV treatment sector thanks to drugs like Truvada (emtricitabine and tenofovir disoproxil fumarate) and Atripla (favirenz/emtricitabine/tenofovir disoproxil fumarate), but ViiV is fighting back.

ViiV agrees $1.5bn deal to acquire BMS' HIV assets

ViiV agrees $1.5bn deal to acquire BMS' HIV assets cobicistat), Sustiva (efavirenz) and big-selling Atripla (efavirenz, emtricitabine, and tenofovir).

ViiV boosted by positive phase III results for HIV drug Triumeq

ViiV boosted by positive phase III results for HIV drug Triumeq The current HIV fixed-dose combination market leader is by Gilead's Atripla (tenofovir, emtrcitabine and efavirenz), which in 2013 achieved sales of $3.6bn.

1 2 3 4 5 6 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics